AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PMV Pharmaceuticals, Inc. Director's Dealing 2023

Sep 18, 2023

34350_dirs_2023-09-18_f9a27ab3-db1f-4f16-866e-24436bf5c8d6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2023-09-15

Reporting Person: Jalota Deepika (Chief Development Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-15	Common Stock	S	4104	$6.62	Disposed	29946	Direct

Footnotes

F1: The reported shares were sold to cover the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.